-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLS-009 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLS-009 in Extranodal...
-
Consumer Insights
NewMass Affluent Banking in Western Europe – Regional Breakdown by Market Trends, Investment Preferences and Competitor Benchmarking
Mass Affluent Banking Market in Western Europe Report Overview Western Europe has an attractively large segment of the mass affluent population accounting for over 90% of the liquid asset value invested in the region. Equities and mutual funds are the most popular assets besides private pensions and investment properties. Achieving a financially secure and comfortable retirement is the main financial goal of mass affluents. Hence, a large percentage of them prefer accumulating assets instead of repaying their debts. This indicates...
-
Sector Analysis
Italy Cards and Payments – Opportunities and Risks to 2027
Italy Cards and Payments Market Report Overview The annual value of card transactions in the Italy cards and payments market was $408.5 billion in 2023. The value is expected to grow at a CAGR of more than 10% during 2023-2027. Cash remains an integral part of the Italian consumer payments landscape. The government is making efforts to promote electronic payments including improving payment card acceptance, mandating certain merchant categories to accept electronic payments, and offering tax benefits to merchants for...
-
Product Insights
NewNet Present Value Model: SELLAS Life Sciences Group Inc’s NeuVax
Empower your strategies with our Net Present Value Model: SELLAS Life Sciences Group Inc's NeuVax report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rogaratinib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rogaratinib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rogaratinib in Metastatic Breast Cancer Drug Details: Rogaratinib (BAY-1163877) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Multiple Myeloma (Kahler Disease) Drug Details: Galinpepimut-S is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Budigalimab in Small-Cell Lung Cancer Drug Details: Budigalimab (ABBV-181) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Peritoneal Cancer Drug Details: Galinpepimut-S is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Small-Cell Lung Cancer Drug Details: Galinpepimut-S is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Fallopian Tube Cancer Drug Details: Galinpepimut-S is under...